BioLineRX ADR News

0,885 $ -0,11% -0,001 $
In Euro: 0,7698 € | 20.08.18 22:00:00 Uhr Nasdaq | Mehr Kurse »
WKN: A1JHLB
ISIN: US09071M1062
US-Symbol: BLRX
Typ: Aktie

BioLineRX ADR News

  
13.08.18 BioLineRx Reports Second Quarter 2018 Financial Results PR Newswire
07.08.18 BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization PR Newswire
06.08.18 BioLineRx to Report Second Quarter 2018 Results on August 13, 2018 PR Newswire
01.08.18 BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors PR Newswire
30.07.18 BioLineRx Announces Expansion of Immuno-​Oncology Collaboration in Pancreatic Cancer PR Newswire
18.06.18 BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients PR Newswire
13.06.18 BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference PR Newswire
22.05.18 BioLineRx Reports First Quarter 2018 Financial Results PR Newswire
17.05.18 BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients PR Newswire
17.05.18 BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation PR Newswire
16.05.18 BioLineRx to Report First Quarter 2018 Results on May 22, 2018 PR Newswire
16.05.18 BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia PR Newswire
26.03.18 BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors PR Newswire
14.03.18 BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference PR Newswire
06.03.18 BioLineRx Reports Year End 2017 Financial Results PR Newswire
27.02.18 BioLineRx to Report Annual 2017 Results on March 6, 2018 PR Newswire
06.02.18 BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13 PR Newswire
23.01.18 BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-​Specific T-cells PR Newswire
23.01.18 BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-​Clinical Studies PR Newswire
17.01.18 BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer PR Newswire
21.12.17 BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients PR Newswire
05.12.17 BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY PR Newswire
04.12.17 BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML PR Newswire
21.11.17 BioLineRx Reports Third Quarter 2017 Financial Results PR Newswire
20.11.17 BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium PR Newswire
16.11.17 BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York PR Newswire
09.11.17 BioLineRx to Report Third Quarter 2017 Results on November 21, 2017 PR Newswire
02.11.17 BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment PR Newswire
18.10.17 BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration PR Newswire
26.09.17 BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration PR Newswire
07.09.17 BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York PR Newswire
21.08.17 BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization PR Newswire
08.08.17 BioLineRx Reports Second Quarter 2017 Financial Results PR Newswire
02.08.17 BioLineRx to Report Second Quarter 2017 Results on August 8, 2017 PR Newswire
26.07.17 BioLineRx Announces Additional Investment From BVF Partners L.P. PR Newswire
10.07.17 BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration PR Newswire
01.06.17 BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors PR Newswire
25.05.17 BioLineRx Reports First Quarter 2017 Financial Results PR Newswire
22.05.17 BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML PR Newswire
16.05.17 BioLineRx to Report First Quarter 2017 Results on May 25, 2017 PR Newswire
03.05.17 BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA PR Newswire
05.04.17 BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares PR Newswire
31.03.17 BioLineRx Prices $25 Million Underwritten Public Offering PR Newswire
30.03.17 BioLineRx Announces Underwritten Public Offering of its American Depositary Shares PR Newswire
27.03.17 BioLineRx's AGI-134 to be Presented at AACR 2017 PR Newswire
23.03.17 BioLineRx Reports Year End 2016 Financial Results PR Newswire
23.03.17 BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-​Oncology Pipeline PR Newswire
20.03.17 BioLineRx Provides Update on Phase 2 Open-​Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment PR Newswire
16.03.17 BioLineRx to Report Annual 2016 Results on March 23, 2017 PR Newswire
07.02.17 BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14 PR Newswire

Newssuche

  
}